Can Ingrezza (valbenazine) help or worsen tremors in patients with underlying conditions such as tardive dyskinesia, Parkinson's disease, or essential tremor?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ingrezza and Tremors: Effect Profile

Ingrezza (valbenazine) can worsen tremors as a side effect by causing drug-induced parkinsonism, which includes tremor as a cardinal feature, and this occurs in approximately 3-5% of patients treated for tardive dyskinesia. 1

Understanding the Mechanism and Risk

  • Ingrezza is a VMAT2 inhibitor that works by reducing dopaminergic transmission, which is the same mechanism that can precipitate parkinsonian symptoms including tremor 1

  • The FDA label explicitly warns that "INGREZZA and INGREZZA SPRINKLE may cause parkinsonism" with specific mention of "shaking (tremors)" as one of the Parkinson-like symptoms to monitor 1

  • In controlled trials for tardive dyskinesia, parkinson-like adverse events occurred in 3% of Ingrezza-treated patients versus <1% of placebo patients 1

  • Postmarketing reports have documented severe parkinsonism in patients taking Ingrezza, with most cases occurring within the first two weeks after starting or increasing the dose 1

Clinical Distinction: Tardive Dyskinesia vs. Tremor

  • Ingrezza is FDA-approved specifically for tardive dyskinesia, which characteristically involves choreiform and athetoid movements—NOT tremor 2, 3

  • Classic tardive dyskinesia presents with rapid involuntary facial movements and extremity movements, but tremor is not a primary feature of TD 3

  • If a patient on antipsychotics develops tremor, this more likely represents drug-induced parkinsonism rather than tardive dyskinesia, especially if occurring early in treatment 3

Management Recommendations

  • Reduce the dose or discontinue Ingrezza if clinically significant parkinson-like signs or symptoms (including tremors) develop 1

  • The FDA label emphasizes that drug-induced parkinsonism "has the potential to cause more functional disability than untreated chorea" in some patients 1

  • Associated symptoms with Ingrezza-induced parkinsonism include falls, gait disturbances, tremor, drooling, and hypokinesia 1

  • In cases where follow-up was available, parkinson-like symptoms resolved following discontinuation of Ingrezza therapy 1

Important Caveats

  • Do NOT use anticholinergics (like benztropine) to treat tremor if it's part of tardive dyskinesia, as anticholinergics can worsen TD 2

  • However, if the tremor represents drug-induced parkinsonism (not TD), anticholinergic agents may be beneficial 3

  • The critical clinical decision is distinguishing between drug-induced parkinsonism (where tremor is expected and anticholinergics may help) versus tardive dyskinesia (where tremor is atypical and anticholinergics worsen the condition) 2, 3

Bottom Line for Clinical Practice

Ingrezza does not help tremors—it can cause or worsen them through drug-induced parkinsonism. The medication is designed to treat the choreiform movements of tardive dyskinesia, not tremor disorders. If tremor develops or worsens on Ingrezza, dose reduction or discontinuation should be strongly considered rather than adding additional medications. 1

References

Guideline

Management of Tardive Dyskinesia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Tardive Dyskinesia and Tardive Tremor

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.